What is venture philanthropy?

EBRP's Venture Philanthropy model leverages concepts from principal investing and applies them towards achieving philanthropic goals. When making a grant to a research project, we retain the added upside of generating a recurring donation stream if the therapy or product is commercially successful. That revenue then goes back into funding additional EB research, giving your donation the potential to grow to multiples of its original value.

​Historically, non-profits have passed on these financial benefits. Instead, EBRP participates in them, making philanthropy sustainable. Through partnerships with the University of Minnesota and Stanford University, EBRP pioneered the venture agreements that we use for all grantmaking.

industry leadership

---

Harvard Business School's Kraft Precision Medicine Accelerator focuses on advancing therapies for patients by employing modern business plans that keep up with cutting-edge science. As a member, EBRP advises the group on Venture Models to accelerate cures.

---

Seizing Opportunities in the Current Life Sciences Environment: Venture Approaches details 4 venture philanthropy case studies that exhibit how EBRP is venturing into cures.

READ WHITE PAPER

---

Innovative Funding Models to Drive Cures highlights EBRP as a leader in the Venture Philanthropy.

Read Article

---

Venture Models can Accelerate Cures, but aren't for the Faint of Heart covers the evolution of EBRP's venture model, from funding academic medical centers, to parterning with biotech and pharma companies, forming new companies, and creating a holding company for rare derm biotechs.

Read Article

---

Patient-driven foundations are focused on the asset that can’t be replaced—time. " The Milken Institute's FasterCures took a deep dive into our  Venture Philanthropy model in The Research Acceleration and Innovation Network (TRAIN) webinar series. The discussion focuses on the formation of Wings Therapeutics, facilitated by EBRP, to take over development of ProQR Therapeutics' EB therapy. 

Read Case Study

Learn More

To realize our vision of a world without EB, we're building a model based on three core pillars: Share, Collaborate, Cure. Learn more about our Venture Into Cures methodology to accelerate the path to EB therapies.

Read Campaign Prospectus

CEO michael hund on venture philanthropy

Global Genes covers our model from Venture Philanthopy, to strategic partnerships, and our vision for a first-of-its kind data platform to advance treatments and cures for EB in this case study.

Read Case Study

in the press

listen here

listen here

OCTOBER 26, 2022
In this episode of OnAir: Health Care, Akin Gump senior policy advisor Matthew Hittle and consultant Dr. Mario Ramirez welcome Michael Hund of EB Research Partnership. Among other topics, they discuss the severe challenges of the disease EB, or epidermolysis bullosa, the venture philanthropy model of funding research into rare diseases, and leading technologies in treating EB and other genetic diseases.

OCTOBER 26, 2022
Tune in to learn how the “venture philanthropy” model EBRP uses differs from typical investing, and hear about important fundraising events for EB including Venture Into Cures hosted by Spiderman actor Tom Holland. And be sure to stay tuned to hear their advice to medical providers on the importance of building rapport with patient families, and taking an interdisciplinary approach to treating rare disorders.

---

watch here

Read More

AUGUST 31, 2022
In each episode of Break Everything... in Healthcare, healthcare leaders dream BIG about paradigm-shifting ways they want to make the Healthcare system more compassionate, effective, and efficient. In this episode, Lisa interviews Michael Hund, MBA, the CEO of EB Research Partnership, a game-changing medical research organization dedicated to curing the life-threatening genetic skin disease Epidermolysis Bullosa (EB) and pioneering the innovative business model of Venture Philanthropy. ​

AUGUST 13, 2020
​"Just because you're a nonprofit doesn't mean you can't act like a business" says EBRP CEO Michael Hund in USA Today. As a member of Harvard Business School's Kraft Precision Medicine Accelerator, a program that offers guidance to medical nonprofits in search of cures, he advises the group on navigating venture philanthropy. Although COVID-19 has posed unique challenges to the medical research community, EBRP has forged ahead to advance therapies for EB.